Captain T Cell Secures €8.5m Seed Financing Round (2024-05-22)

Cell therapy

Captain T Cell GmbH, a biotechnology company developing next-generation T cells against solid tumors, today announced the successful closing of a seed financing round totaling € 8.5 million. A syndicate of experienced life science investors including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H participated in the round. In addition, the German Federal Ministry of Education and Research (BMBF) is supporting the Company through its prestigious GO-Bio program. The financing also marks the appointment of biotech veteran Jörn Aldag as Chairman of the Board of Directors.

The funds will be used to further progress Captain T Cell’s first-in-class lead program towards the clinic along with a novel allogeneic platform for off-the-shelf treatments of solid tumors.


More infos

Back to news